Predictors of failure of Helicobacter pylori eradication and predictors of ulcer recurrence: a randomized controlled trial

Clin Invest Med. 1999 Oct;22(5):185-94.

Abstract

Objective: In light of evidence that Helicobacter pylori treatment fails 5% to 20% of the time, the objective of this study was to determine predictors of unsuccessful H. pylori eradication and of duodenal ulcer recurrence.

Design: Randomized, double-blind, placebo-controlled trial.

Setting: Gastroenterology services of 2 general hospitals in Montreal, Que.

Patients: All patients (aged 16 to 90) with an endoscopically proven duodenal ulcer within the previous year and H. pylori infection detected on antral biopsy were asked to participate; 85 were included.

Interventions: Patients were randomized in double-blind fashion to 1 of 2 eradication therapies, consisting of metronidazole, bismuth subcitrate and either amoxicillin or placebo. Endoscopy was performed at follow-up every 3 months for 12 months.

Outcome measures: Demographic data, characteristics of patients and disease, previous history and family history of ulcer disease, compliance at day 10 and day 28 of therapy; in vitro metronidazole resistance of H. pylori; eradication of H. pylori (determined by endoscopic biopsy 3 months after therapy); and ulcer recurrence within 12 months after therapy.

Results: Metronidazole resistance (odds ratio [OR] 0.11, 95% confidence interval [CI] 0.017 to 0.69) was the only independent predictor of eradication. Compliance (as defined in the study), density of organisms on culture, as well as several other factors examined, were not significant predictors. Treatment group, although a significant factor on univariate analysis, was not an independent predictor on multivariate analysis, as there were relatively good eradication rates (82% and 97% among compliant patients) in both groups. With regard to ulcer recurrence, 3 independent predictors were identified: failed H. pylori eradication (OR 86.5, 95% CI 4.2 to 1769), unemployment (OR 13.2, 95% CI 1.8 to 95) and a family history of ulcer disease (OR 12.2, 95% CI 1.2 to 128).

Conclusions: The best predictor of ulcer recurrence is failure of H. pylori eradication, which, in turn, depends on metronidazole resistance. Hence, treatments containing metronidazole should be avoided in populations with high rates of metronidazole resistance. A family history of ulcer disease and unemployment were also predictors of ulcer recurrence, which suggests a potential role for treatment of contacts.

Publication types

  • Clinical Trial
  • Randomized Controlled Trial
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adolescent
  • Adult
  • Aged
  • Aged, 80 and over
  • Amoxicillin / therapeutic use
  • Anti-Bacterial Agents / therapeutic use*
  • Anti-Ulcer Agents / therapeutic use*
  • Duodenal Ulcer / drug therapy*
  • Duodenal Ulcer / microbiology
  • Duodenal Ulcer / prevention & control
  • Endoscopy
  • Female
  • Follow-Up Studies
  • Helicobacter pylori / drug effects*
  • Humans
  • Male
  • Metronidazole / therapeutic use
  • Middle Aged
  • Organometallic Compounds / therapeutic use
  • Penicillins / therapeutic use
  • Predictive Value of Tests
  • Quebec
  • Recurrence
  • Treatment Failure

Substances

  • Anti-Bacterial Agents
  • Anti-Ulcer Agents
  • Organometallic Compounds
  • Penicillins
  • Metronidazole
  • Amoxicillin
  • bismuth tripotassium dicitrate